RCT: Bendamustine plus rituximab vs CHOP plus rituximab as first-line treatment for indolent and mantle-cell lymphomas
Source: Lancet
Area: News
Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is considered the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma, however there are no randomised comparative study data to show that this regimen is better than other chemotherapy regimens. Bendamustine plus rituximab is effective for relapsed or refractory disease and based on long-standing experience of its use in Germany, this prospective, randomised, open-label non-inferiority study compared this regimen with ...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
LCNDG Rapid Review: Bendamustine for relapsed follicular lymphoma refractory to rituximab
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
The manufacturer of bendamustine (Napp Pharmaceuticals) was invited to submit evidence for a NICE single technology appraisal (STA) in May 2010. In June 2010, the manufacturer informed NICE that it would not be making an evidence submission because it was unable to identify comparative clinical evidence suitable for a NICE appraisal in people with rituximab refractory disease. The manufacturer indicated that further research was ongoing but data would not be available in a time frame that would allow NICE to produce timely guidance. NICE ther...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
BRIGHT Not So Clear on Lymphoma ChoiceBRIGHT Not So Clear on Lymphoma Choice
The BRIGHT study presented at ASH 2012 showed R-bendamustine to be noninferior to R-CHOP, but what role each regimen plays in lymphoma management is still unclear, says Dr. Bruce Cheson. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
BRIGHT Shines Light on R-Bendamustine in LymphomaBRIGHT Shines Light on R-Bendamustine in Lymphoma
At 50 years of age, bendamustine holds its own against standard regimens in lymphoma. Medscape Hematology-Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology Expert Interview Source Type: news
NCCN Updates Non-Hodgkin ’s Lymphoma Guidelines
FORT WASHINGTON, Pa., April 22, 2008 — The National Comprehensive Cancer Network (NCCN) announces several new updates to the NCCN Clinical Practice Guidelines in Oncology Non-Hodgkin’s Lymphoma (NHL). These changes highlight leading developments in the treatment of NHL and represent the recognized standard for clinical care in onco logy in both the community and the academic practice settings.
The NHL Guidelines now include bendamustine (Treanda, Cephalon) as a treatment option for chronic lymph... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - April 22, 2008 Category: Cancer & Oncology Source Type: news
NCCN Updates Non-Hodgkin’s Lymphoma Guidelines
FORT WASHINGTON, Pa., April 22, 2008 — The National Comprehensive Cancer Network (NCCN) announces several new updates to the NCCN Clinical Practice Guidelines in Oncology Non-Hodgkin’s Lymphoma (NHL). These changes highlight leading developments in the treatment of NHL and represent the recognized standard for clinical care in oncology in both the community and the academic practice settings.
The NHL Guidelines now include bendamustine (Treanda, Cephalon) as a treatment option for chronic lymph... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - April 22, 2008 Category: Cancer & Oncology Source Type: news
